# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $4...
Insmed is reiterating its sales guidance for full-year 2024 global ARIKAYCE revenues in the range of $340 million to $360 mil...
Insmed (NASDAQ:INSM) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.23) by 13....
Truist Securities analyst Nicole Germino initiates coverage on Insmed (NASDAQ:INSM) with a Buy rating and announces Price Ta...
Barclays analyst Leon Wang maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $37 to $40.
Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and maintains $55 price target.
- SEC Filing